Strategic Platform Expansion and Partnership Growth
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Performance is driven by a strategic focus on diversified, durable revenue streams facilitated by highly differentiated technology platforms that accelerate partnership and program progression.
-
Secured a major new partnership with Eli Lilly for a novel ion channel program, providing an upfront payment and eligibility for up to $370 million in milestones plus tiered royalties.
-
Expanded commercial access to the xPloration AI-powered screening platform to address a $500 million market opportunity by leveraging lab automation and big data generation.
-
Launched OmniTides, a peptide discovery offering that utilizes 'biological intelligence' from transgenic chickens to provide an integrated discovery-to-synthesis workflow.
-
Maintained a robust partner ecosystem with 111 active partners, including 9 of the 10 largest pharmaceutical companies in the world, demonstrating the quality of the partner base.
-
Achieved a significant clinical milestone with the approval of batoclimab in China, marking the fourth drug approved from the company's technology platform.
-
Strategic positioning focuses on generating high-quality data layers relevant to human therapeutics, which management believes makes the business model naturally AI-friendly.
Guidance Increases and Clinical Momentum
-
Raised 2026 revenue guidance to a range of $35 million to $39 million, driven by higher-than-expected milestone revenue and controlled operating expenses.
-
Projecting xPloration revenue to double in 2027 and double again in 2028 as the installed base of instruments drives recurring high-margin consumable and software revenue.
-
Anticipates a busy clinical calendar with primary completion of clinical trials by partners over the next 18 months, representing a substantial pool of programs tied to $340 million in potential milestone payments., which could trigger portions of $340 million in remaining potential milestones.
-
Expects milestones to remain the primary revenue driver for the next two years, with royalties projected to become a larger growth factor starting in late 2028 with assets like IMVT-1402.
-
Guidance for year-end cash balance is $53 million to $57 million, positioning the business to be essentially cash flow breakeven for the full year 2026.
Operational Metrics and Structural Dynamics
-
Active programs increased to 433, with more than 98% of these programs carrying contracted future economics and an average royalty rate of approximately 3.4%.
-
A single partner attrition event occurred due to a larger partner acquiring a smaller one, which management views as a positive indicator for the progression of assets discovered with their tech.
-
Service revenue growth was driven by new ion channel agreements, with contributions from the Eli Lilly collaboration expected to begin in the fourth quarter.
-
Operating expenses decreased year-to-date due to internal efficiencies, though comparisons were skewed by a prior-year gain and a first-quarter non-cash write-off.
Q&A Session Insights
xPloration commercial pipeline and revenue model
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
-
The capital sales cycle for xPloration instruments typically ranges from 12 to 18 months as customers navigate different capital budgeting processes.
-
Revenue is currently dominated by instrument placements, but recurring streams from proprietary chips and software are expected to scale as customers run more experiments.
-
Management is seeing interest across big pharma, global CROs, and specialty biotech companies, with feedback translating into placements.
Teva partnership (TEV-'408) and indication expansion
-
Positive celiac data supports Teva's peak sales estimates of $1.5 billion to $2 billion for that indication, with additional potential in vitiligo estimated at $1 billion.
-
The asset is being explored for further applications in alopecia areata, eosinophilic esophagitis, and atopic dermatitis, which could significantly expand the target patient population.
Operating expense sustainability during growth phases
-
Management believes the core antibody business is rightsized and does not require additional infrastructure to support growing partnerships.
-
Future investments will be selectively allocated to xPloration by reallocating savings found in other areas of the business, avoiding dramatic increases in total operating expense.
Batoclimab royalty contribution and China launch
-
Following NMPA approval in China, partner Harbour Biomed is preparing for a launch soon, though specific pricing and royalty impacts remain too early to determine.
-
The approval represents the fourth drug from the platform, and the asset will transition to the 'approved' column in future status updates.
